New Cosentyx data confirms robust efficacy and QoL improvements in scalp psoriasis

Swiss pharma giant Novartis (NOVN: VX) has presented new Cosentyx (secukinumab) data from the prospective Phase III SCALP study which showed significant improvement in skin clearance with Cosentyx in patients with scalp psoriasis.

Due to the presence of hair, scalp psoriasis is particularly difficult to treat with common topical and phototherapy options. These study results were presented at the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California. Novartis shares edged up 1.48% to 80.80 Swiss francs on Friday.

"Scalp psoriasis can be painful and in some cases, can lead to temporary hair loss and cause the involved area to crack and bleed," said Kristian Reich, Georg-August-University Göttingen and Dermatologikum Hamburg, Germany. "The data presented at AAD is encouraging for both physicians and patients, who can have greater trust in Cosentyx as a complete treatment option for patients with plaque psoriasis who want to avoid scalp and other manifestations of psoriasis," Dr Reich added.